Luminex (NASDAQ:LMNX) Q2 results:
Total revenue: $109.5M (+31.8%); Assays: $61.2M (+94.9%). Sales growth driven by demand for pandemic-related tests.
Net income: $12.5M (+355.1%); EPS: $0.27 (+345.5%).
Cash flow ops: $31.3M (+430.5%).
Q3 guidance: Revenue: at least $100M (+26%). Consensus: $107M.
2020 guidance: Revenue: at least $415M (+24%). Consensus: $387M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.